Picture of MGC Pharmaceuticals logo

MXC MGC Pharmaceuticals Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-5.55%
3m-12.17%
6m-80.32%
1yr-96.49%
Volume Change (%)
10d/3m+13.42%
Price vs... (%)
52w High-96.38%
50d MA+5.2%
200d MA-76.11%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value11.71
Price to Tang. Book11.71
Price to Free Cashflown/a
Price to Sales11.99
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-316.25%
Return on Equityn/a
Operating Margin-1175.76%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of MGC Pharmaceuticals EPS forecast chart

Profile Summary

MGC Pharmaceuticals Ltd is an Australia-based pharmaceutical company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its central business strategy revolves around the development and supply of medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia. It maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products in the developmental stages. Its clinical trials include CannEpil, CimetrA and ArtemiC. It has a growing patient base in Australia, the United Kingdom, Brazil, and Ireland. The Company's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
October 21st, 2005
Public Since
December 21st, 2006
No. of Shareholders
10,119
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
36,491,631

MXC Share Price Performance

Upcoming Events for MXC

Full Year 2024 MGC Pharmaceuticals Ltd Earnings Release

Similar to MXC

Picture of Acrux logo

Acrux

au flag iconAustralian Stock Exchange - SEATS

Picture of AFT Pharmaceuticals logo

AFT Pharmaceuticals

au flag iconAustralian Stock Exchange - SEATS

Picture of Althea group logo

Althea group

au flag iconAustralian Stock Exchange - SEATS

Picture of Auscann group logo

Auscann group

au flag iconAustralian Stock Exchange - SEATS

Picture of Biome Australia logo

Biome Australia

au flag iconAustralian Stock Exchange - SEATS

FAQ